Pantothenate-kinase-associated neurodegeneration (PKAN), also known as Hallervorden-Spatz Disease, is the most common form of neurodegeneration involving brain iron accumulation. Most patients with classic PKAN are wheelchair-bound by their midteens. 1 The first-line treatment for obstructive sleep apnea (OSA), one of the most common sleep disorders, is continuous positive airway pressure (CPAP) therapy. Dystonia or dyskinesia hinders the application of CPAP therapy. There have been a few reports on the treatment of OSA by using invasive procedures including intrathecal baclofen or tracheostomy in patients with laryngeal dystonia and severe bulbar dysfunction. 2 However, evidence is lacking for the usefulness of CPAP in patients with severe dystonia and OSA. Herein we report a case of PKAN and OSA treated with CPAP, with favorable acceptance and compliance.
interna could reduce inhibitory outputs to the pedunculopontine nuclei, which are the muscle tone regulators of REM sleep in patients with PKAN. 5 In our patient, AHI during REM sleep was twice as high as that during non-REM sleep. Thus, the phenotype of OSA in patients with PKAN could differ from that in patients without dystonia. This is the first report on the usefulness of CPAP therapy in a patient with PKAN. Clinicians should diagnose and treat OSA despite the presence severe dystonia or the disabled state of patients. Further studies are needed to elucidate the pathogenesis and efficacy of CPAP therapy in patients with PKAN and OSA. 
